IntelliCyt Launches iQue Screener for Multiplexed Screening of Suspension Assays

Share Article

IntelliCyt also announced it obtained CE Mark for the iQue Screener and has opened a commercial office in California.

IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the commercial launch of their new iQue™ Screener. The system is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools.

IntelliCyt also announced it has obtained the CE Mark for the iQue Screener clearing it to sell it in the European Union and other countries recognizing the CE Mark. The company also announced that it has opened an office in California to support its growing commercial operations.

“Reception to the iQue Screener since our introduction at the Society for Laboratory Automation and Screening (SLAS) in January has been very positive,” commented Terry Dunlay, CEO at IntelliCyt. “Our early access customers have praised the system, which has enabled them to drastically reduce time to final result and cost for critical assays.”

“As part of our growth, we have opened an office in Los Altos, California for our expanding sales, marketing and business development functions,” Dunlay continued. “In addition to supporting our growth globally, the office is located close to the important Bay Area and San Diego biotechnology markets.”

IntelliCyt’s iQue system is the first high-throughput, high-content fully integrated analyzer designed for rapid screening of cells and beads in suspension. Unlike other screening technologies that provide data on a per well basis, IntelliCyt’s technology provides information-rich data on a cell-by-cell basis in 96- and 384-well microplates. Micro-volume sample delivery combined with rapid sample processing and highly sensitive multiplexing capabilities let researchers in many fields screen large libraries at unprecedented speed and also drastically reduce costs.

About IntelliCyt Corporation

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

R. Terry Dunlay, President and CEO
Visit website